Friends! In this video, I'm going to do an analysis on Mercado Libre stock or MELI stock
2 extracted signals · 2 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 08 Jan 2026, 00:41 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The analysis focuses on MicroStrategy's (MSTR) financial strategy, highlighting its current valuation at 1.01 times its Net Asset Value (NAV), a notable deviation from its historical premium of 2.0x to 2.3x NAV. The speaker posits this as an asymmetrical investment opportunity, with significant potential for price appreciation if the NAV premium is restored. MicroStrategy's core strategy involves increasing its Bitcoin (BTC) holdings per share, a metric termed 'BTC Yield,' which has shown consistent growth since 2020. This approach has allowed MSTR to outperform Bitcoin, with returns of 1178.1% compared to Bitcoin's 676.2% since 2020, despite the recent premium collapse. The company funds its Bitcoin acquisitions through convertible debt and preferred equity offerings, referred to as 'digital credit.' While preferred equity serves as a permanent capital base, it necessitates substantial annual dividend and interest payments, amounting to $831 million. MicroStrategy's software business generates approximately $90 million in gross profit, which covers operational expenses but is insufficient to meet dividend obligations without external financing. This business model relies heavily on maintaining an NAV premium to facilitate new equity issuance. Should MSTR's stock consistently trade below 1.0 times NAV, it would lead to shareholder dilution, potentially forcing the company to liquidate Bitcoin holdings to cover liabilities. Currently, USD reserves of $2.25 billion cover dividends for 32.5 months. The long-term sustainability of this model is questioned by the analyst if the premium is not maintained, leading to potential selling pressure on Bitcoin.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

